<DOC>
	<DOCNO>NCT00506350</DOCNO>
	<brief_summary>The present study design evaluate reactogenicity immunogenicity one two booster administration influenza pandemic candidate vaccine ( GSK1562902A ) adult age 19 61 year , previously vaccinate 2 dos pandemic candidate vaccine . Fifty new subject participate primary study ( 106750 , NCT00309634 ) recruit . This protocol post deal objective &amp; outcome measure booster phase . The objective &amp; outcome measure primary phase present separate protocol posting ( NCT00309634 )</brief_summary>
	<brief_title>Evaluate Reactogenicity &amp; Immunogenicity Influenza Pandemic Candidate Vaccine ( GSK1562902A ) Primed Adults</brief_title>
	<detailed_description>The present study design evaluate reactogenicity immunogenicity one two booster administration influenza pandemic candidate vaccine ( GSK1562902A ) adult age 19 61 year , previously vaccinate 2 dos pandemic candidate vaccine . The persistence antibody analyse 6 , 12 , 18 24 month .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects investigator believe comply requirement protocol enrol study . For previously prim subject : participation primary study ( NCT00309634 ) . For unprimed subject : male female include , 19 61 year age time first vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . If subject female , must nonchildbearing potential childbearing potential , must practice adequate contraception 30 day prior vaccination , negative pregnancy test continue precaution 2 month completion vaccination series . Use investigational nonregistered product ( drug vaccine ) study vaccine ( ) within 30 day precede first dose study vaccine , plan use study period . For unprimed subject participate primary study ( NCT00309634 ) : Chronic administration ( defined 14 day ) immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/ administration licence vaccine foreseen study protocol within 2 week ( inactivated vaccine ) 4 week ( live vaccine ) first dose vaccine ( ) . Concurrently participate another clinical study , time study period , subject expose investigational noninvestigational product ( pharmaceutical product device ) . Applicable control group : previous vaccination pandemic candidate vaccine vaccine contain investigational vaccine adjuvant . History hypersensitivity vaccine . Any confirm suspected immunosuppressive immunodeficient condition , base medical history physical examination ( laboratory testing require ) . History allergic disease reaction likely exacerbate component vaccine ( ) . Major congenital defect serious chronic illness . History neurological disorder seizure . Acute disease time enrolment . Acute chronic , clinically significant pulmonary , cardiovascular , hepatic renal functional abnormality , determine physical examination laboratory screen test . Serious chronic disease include medically significant chronic pulmonary , cardiovascular , renal , neurological , psychiatric metabolic disorder , determine medical history physical examination . Any condition , opinion investigator , prevents subject participation study . Lactating female . History chronic alcohol consumption and/or drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>61 Years</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>